Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model

AIM: To examine the effects of the endothelin type A receptor antagonist ambrisentan on hepatic steatosis and fibrosis in a steatohepatitis mouse model. METHODS: Fatty liver shionogi (FLS) FLS-ob/ob mice (male, 12 wk old) received ambrisentan (2.5 mg/kg orally per day; n = 8) or water as a control (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Hepatol
Main Authors: Okamoto, Toshiaki, Koda, Masahiko, Miyoshi, Kennichi, Onoyama, Takumi, Kishina, Manabu, Matono, Tomomitsu, Sugihara, Takaaki, Hosho, Keiko, Okano, Junichi, Isomoto, Hajime, Murawaki, Yoshikazu
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2016
Assuntos:
Basic Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4976212/
https://ncbi.nlm.nih.gov/pubmed/27574547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v8.i22.933
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados